Business
PDS second quarter 2019 financial results
PDS second quarter 2019 financial results.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 6038H NetScientific PLC 01 August 2019 \n\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014\nNetScientific plc\n(\"NetScientific\" or the \"Company\")\nPDS Biotechnology Corporation Reports Second Quarter 2019 Financial Results\nNetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (\"PDS\") (Nasdaq: PDSB) has released its unaudited financial results for the second quarter ended 30 June 2019.\nNetScientific holds 8.15% of PDS on a fully diluted basis.\nThe full details of the announcement is set out below and the financial report can be found here: http://investors.pdsbiotech.com/financial-information/sec-filings\nFor more information, please contact:\n \n\n\n\n\n NetScientific\n Ian Postlethwaite, CEO / CFO\n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\nWHIreland (NOMAD, Financial Adviser and Broker)\nChris Fielding / Jessica Cave\n\n\nTel: +44 (0)20 7220 1666\n\n\n\n\nMO PR ADVISORY (Press Contact)\nMo Noonan\n\n\nTel: +44 (0)78 7644 4977\n\n\n\n\n \nPDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update\nBerkeley Heights, NJ, August 1, 2019 - PDS Biotechnology Corporation (\"PDS Biotechnology\") (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced its financial results for the second quarter ended June 30, 2019.\nQ2 2019 and Recent Business Highlights\n• Signed Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to perform a Phase 2 clinical study of\n· PDS0101 in combination with other immune-modulating agents in advanced HPV-related cancers;\n• Announced peer-reviewed publication in the Journal of Immunology supporting the novel mechanism of action of PDS' proprietary Versamune®\n· platform in cancer immunotherapy;\n• Granted U.S. and European patents for Versamune - GM-CSF combination to overcome tumor immune suppression; and\n• Appointed industry veteran Stephen Glover as Chairman of the Board.\n\"We have been working dili...